/ Library/ Chemotherapy Drug Taxotere Linked to Permanent Hair Loss
October 24, 2016 Social Share
Our drug injury lawyers are currently investigating potential lawsuits for persons who have suffered from alopecia, baldness, and permanent hair loss as a result of taking the chemotherapy drug Taxotere. Call our Indianapolis office for a free case evaluation at 317.920.6400 or reach us through our online form.
Taxotere (generic Docetaxel) is a chemotherapy drug used primarily in the treatment of metastasized or advanced-stage breast cancer. Taxotere is manufactured by Sanofia-Aventis, and was first approved for the treatment of breast cancer in the U.S. in 1996. Since then, Taxotere has been approved for the treatment of lung cancer, gastric (stomach) cancer, and prostate cancer.
Taxotere is a common treatment method for breast cancer. It works by interfering and stopping cancerous cells from multiplying, in turn blocking further cancer growth.
While temporary hair loss is a common side effect of radiation or chemotherapy treatment, permanent hair loss is not typical; the expectation is that hair growth will return to normal post-treatment. Unfortunately, this isn’t always the case.
Many Taxotere users are experiencing complete, permanent hair loss—or alopecia—and never received a sufficient warning of the risk while taking the medication. Had patients been properly warned of the risks, an alternative route (i.e. choosing another medication for treatment that posed no risk of hair loss) could have been an option.
If you were taking Taxotere as part of your breast cancer treatment regiment and your hair still hasn’t begun regrowth, you could be suffering from alopecia. The symptoms include:
There are 2.8 million American women with a history of breast cancer. Of those women, 75% of them are or were prescribed Taxotere for breast cancer treatment. A 2011 study published in the American Journal of Dermatopathology found that chemotherapy drugs that contain taxanes could very well contribute to the development of alopecia.
Come 2012, yet another study published in the Annals of Oncology found the same results: Permanent hair loss was determined a newly reported complication of Taxotere. Twenty white Caucasian females participated in the study, and all but one had no history of alopecia. Therapy to remedy the hair loss proved to be ineffective.
In December 2015, there had been enough reports of alopecia and permanent hair loss in patients treated with Taxotere that the FDA issued a warning. Following the announcement, the FDA updated Taxotere’s warning label to include the potential side effect of developing baldness or alopecia while taking the drug.
From Texas, to Lousiana, to Ohio, to California, to Mississippi, lawsuits have been filed against Sanofi-Aventis for not only failing to disclose the side effects from both the public and medical community, but knowingly hiding the information as to further benefit from Taxotere sales.
Drug injury attorneys across the country agree that, had Sanofi-Aventis disclosed the risks of permanent hair loss after Taxotere treatment, thousands of women could have avoided tremendous mental anguish, pain, and suffering.
Filing a claim to pursue a Taxotere lawsuit can benefit victims by receiving compensation for:
The Indianapolis drug injury attorneys at Wilson Kehoe Winingham have been dedicated to helping wrongfully injured persons for over 30 years. We fight the hardest to remedy the pain and suffering for every client. If you’ve suffered from permanent hair loss or alopecia has a result of taking Taxotere, contact our Indianapolis drug injury attorneys for a free case review. As always, you don’t pay a dime until we recover your losses. Call our drug injury attorneys at 317.920.6400 or fill out an online form today.
Fill out the form below to receive a free and confidential initial consultation.